Abstract: The present invention relates to compounds of Formula (I) that are inhibitors of c-ABL. The invention also relates to pharmaceutical compositions comprising those compounds, and to their use in the treatment or prevention of medical conditions in which inhibition of c-ABL is beneficial. Such medical conditions include neurodegenerative diseases and cancer.
Type:
Application
Filed:
December 16, 2021
Publication date:
March 7, 2024
Applicant:
BENEVOLENTAI BIO LIMITED
Inventors:
Rebecca PAUL, Michael John RAWLING, Christine WATSON
Abstract: The present invention relates to pharmaceutical compositions, such as topical pharmaceutical compositions, comprising certain imidazo[1,2-b]pyridazine compounds and the pharmaceutically acceptable salts and/or solvates of such compounds. The invention also relates to the processes for the preparation of the pharmaceutical compositions, and the uses of such compositions in treating diseases or conditions associated with tropomyosin-related kinase (Trk) activity. More specifically the invention relates to topical pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salts and/or solvates thereof, which are useful in inhibiting Trk.
Type:
Application
Filed:
January 22, 2021
Publication date:
May 18, 2023
Applicant:
BenevolentAI Bio Limited
Inventors:
Nicola Robas, Cameron Robert Stevenson, Emily Anne Gaynor Prothero, Charles Rodney Greenaway Evans
Abstract: The present invention relates to pharmaceutical compositions, such as topical compositions, comprising certain imidazo [1,2-b] pyridazine compounds and the pharmaceutically acceptable salts and/or solvates of such compounds. The invention also relates to the processes for the preparation of the pharmaceutical compositions, and the uses of such compositions in treating diseases or conditions associated with tropomyosin-related kinase (Trk) activity. More specifically the invention relates to topical pharmaceutical compositions comprising compounds of Formula (I) or a pharmaceutically acceptable salts and/or solvates thereof, which are useful in inhibiting Trk.
Type:
Application
Filed:
January 22, 2021
Publication date:
April 13, 2023
Applicant:
BenevolentAI Bio Limited
Inventors:
Nicola Robas, Michael Ashwood, Cameron Robert Stevenson, Emily Anne Gaynor Prothero, Charles Rodney Greenaway Evans
Abstract: The present invention relates to certain imidazo[1,2-b]pyridazine compounds and the pharmaceutically acceptable salts of such compounds. The invention also relates to the processes for the preparation of the compounds, compositions containing the compounds, and the uses of such compounds and salts in treating diseases or conditions associated with tropomyosin-related kinase (Trk), activity. More specifically the invention relates to the compounds and their salts useful as inhibitors of Trk. (I) wherein R1, R2, R3, R4 and R5 are as defined herein.
Abstract: The present invention relates to orexin receptor antagonists, pharmaceutical compositions comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists as medicaments, in particular for treating diseases, disorders, or conditions mediated by orexin receptor activity. More specifically, there is provided a compound of Formula (I) including salts thereof, polymorphs, and isomers thereof (including optical, geometric and tautomeric isomers) as defined herein and isotopically-labelled compounds of Formula (I).